A Phase I/II，Multicenter, Open-Label, Study of a Novel Bruton’s Tyrosine Kinase Inhibitor, Orelabrutinib, in Patients with B-Cell Malignancies

Condition: B-Cell Malignancies

Sponsor: InnoCare Pharma Inc.

Phase: 1/2

A Phase I/II，Multicenter, Open-Label, Study of a Novel Bruton’s Tyrosine Kinase Inhibitor, Orelabrutinib, in Patients with B-Cell Malignancies. This is an open-label, multicenter, Phase I/II study in order to assess the safety, tolerability, PK, and anti-tumor activity of this treatment in patients with different subtypes of lymphoma.